Sanford C. Bernstein began protection on shares of Roivant Sciences (NASDAQ:ROIV – Get Free Report) in a be aware issued to traders on Friday, MarketBeat reviews. The brokerage set an “outperform” score and a $35.00 value goal on the inventory. Sanford C. Bernstein’s value goal would point out a possible upside of 26.35% from the corporate’s present value.
A number of different brokerages have additionally commented on ROIV. HC Wainwright elevated their value goal on Roivant Sciences from $33.00 to $34.00 and gave the corporate a “purchase” score in a report on Wednesday, March 4th. Leerink Companions boosted their goal value on Roivant Sciences from $29.00 to $32.00 and gave the inventory an “outperform” score in a analysis be aware on Monday, December fifteenth. Citigroup upped their goal value on Roivant Sciences from $26.00 to $35.00 and gave the corporate a “purchase” score in a analysis report on Tuesday, February tenth. Jefferies Monetary Group reiterated a “purchase” score on shares of Roivant Sciences in a analysis be aware on Tuesday, March third. Lastly, TD Cowen reissued a “purchase” score on shares of Roivant Sciences in a report on Wednesday, March 4th. 9 analysts have rated the inventory with a Purchase score, one has given a Maintain score and one has issued a Promote score to the inventory. In line with knowledge from MarketBeat, the corporate presently has a consensus score of “Average Purchase” and a consensus goal value of $29.50.
Get Our Newest Analysis Report on ROIV
Roivant Sciences Inventory Down 0.4%
NASDAQ:ROIV opened at $27.70 on Friday. The inventory has a market capitalization of $19.82 billion, a price-to-earnings ratio of -23.68 and a beta of 1.17. Roivant Sciences has a 52 week low of $8.73 and a 52 week excessive of $30.33. The agency has a 50 day shifting common of $25.92 and a 200 day shifting common of $21.25.
Insider Exercise
In associated information, insider Mayukh Sukhatme offered 339,441 shares of the corporate’s inventory in a transaction on Monday, February ninth. The inventory was offered at a mean value of $26.47, for a complete worth of $8,985,003.27. Following the transaction, the insider instantly owned 19,148,664 shares of the corporate’s inventory, valued at $506,865,136.08. This represents a 1.74% lower of their place. The transaction was disclosed in a authorized submitting with the Securities & Change Fee, which is on the market at this hyperlink. Additionally, Director Melissa B. Epperly offered 41,861 shares of the agency’s inventory in a transaction on Monday, March sixteenth. The inventory was offered at a mean value of $28.68, for a complete worth of $1,200,573.48. Following the completion of the transaction, the director owned 15,804 shares of the corporate’s inventory, valued at $453,258.72. This commerce represents a 72.59% lower of their place. The disclosure for this sale is on the market within the SEC submitting. During the last ninety days, insiders offered 6,794,685 shares of firm inventory valued at $173,053,290. 10.80% of the inventory is owned by company insiders.
Institutional Inflows and Outflows
Institutional traders have just lately modified their holdings of the corporate. Morgan Stanley boosted its place in Roivant Sciences by 31.7% within the fourth quarter. Morgan Stanley now owns 58,359,553 shares of the corporate’s inventory valued at $1,266,402,000 after shopping for an extra 14,036,696 shares over the last quarter. Vanguard Group Inc. raised its place in Roivant Sciences by 8.4% in the course of the 4th quarter. Vanguard Group Inc. now owns 42,059,041 shares of the corporate’s inventory price $912,681,000 after shopping for an extra 3,254,113 shares over the last quarter. Rubric Capital Administration LP lifted its stake in Roivant Sciences by 14.7% in the course of the 2nd quarter. Rubric Capital Administration LP now owns 20,370,336 shares of the corporate’s inventory valued at $229,574,000 after buying an extra 2,603,260 shares in the course of the interval. State Avenue Corp lifted its stake in Roivant Sciences by 4.8% in the course of the 2nd quarter. State Avenue Corp now owns 19,773,480 shares of the corporate’s inventory valued at $222,847,000 after buying an extra 911,827 shares in the course of the interval. Lastly, UBS Group AG boosted its holdings in shares of Roivant Sciences by 570.0% within the 4th quarter. UBS Group AG now owns 18,390,792 shares of the corporate’s inventory valued at $399,080,000 after buying an extra 15,645,836 shares over the last quarter. 64.76% of the inventory is at the moment owned by hedge funds and different institutional traders.
Roivant Sciences Firm Profile
(Get Free Report)
Roivant Sciences is a biopharmaceutical firm targeted on the event and commercialization of revolutionary therapies via a community of subsidiary companies generally known as “Vants.” Based in 2014, Roivant acquires or in-licenses clinical-stage property which have progressed past proof of idea and seeks to advance them effectively towards regulatory approval. By organizing every program right into a devoted subsidiary, the corporate goals to streamline decision-making, allocate assets extra successfully, and speed up growth timelines.
The core actions of Roivant contain figuring out promising drug candidates throughout a spread of therapeutic areas, together with neurology, uncommon ailments, immunology, oncology, and ladies’s well being.
Featured Tales
Obtain Information & Scores for Roivant Sciences Each day – Enter your e-mail tackle beneath to obtain a concise each day abstract of the most recent information and analysts’ rankings for Roivant Sciences and associated corporations with MarketBeat.com’s FREE each day e-mail publication.
